Transplant News and Research

RSS

Coronary computed tomographic angiography to evaluate acute chest pain reduces hospital admissions

Hospital admissions at Stony Brook University Medical Center on Long Island were significantly reduced when using coronary computed tomographic angiography (CCTA) to evaluate patients presenting in the emergency department (ED) with acute chest pain (ACP), according to research results presented during a scientific session at the American College of Cardiology's 60th Annual Scientific Session and Expo in New Orleans on April 3.

4 Apr 2011

Abbott and Enanta's ABT-450/r Phase 2 study results against HCV presented at EASL meeting

Abbott and Enanta Pharmaceuticals today announced 12-week results from a Phase 2 study of ABT-450/r, an investigational, oral protease inhibitor being developed for the treatment of hepatitis C infection.

4 Apr 2011

Optimer study highlights economic burden of acute and recurrent CDI in hospital patients

Optimer Pharmaceuticals, Inc. announced today the presentation of information from insurance claims and survey databases highlighting the unmet need for targeted therapies to treat subpopulations at high risk of recurrence of Clostridium difficile infection.

4 Apr 2011

Leukemia & Lymphoma publishes CTI's CPOP phase I/II trial results against NHL

Cell Therapeutics, Inc. announced today that the April 2011 edition of the peer reviewed journal, Leukemia & Lymphoma published results of a phase I/II clinical trial evaluating the effect of cyclophosphamide, pixantrone, vincristine, and prednisone in treating patients with aggressive non-Hodgkin's lymphoma who relapsed following initial therapy with cyclophosphamide, doxorubicin, vincristine, and prednisone.

4 Apr 2011

Boehringer Ingelheim's BI 201335 new data against HCV highlighted at EASL meeting

New data presented today at the International Liver CongressTM 2011, the 46th Annual Meeting of the European Association for the Study of the Liver, in Berlin, highlighted the efficacy of Boehringer Ingelheim's once-daily oral protease inhibitor BI 201335, in both treatment-naïve and -experienced patients with chronic genotype-1 hepatitis C virus infection. Genotype-1 HCV is the most challenging genotype of HCV to treat.

2 Apr 2011

Boehringer Ingelheim advances into Phase 3 clinical trial of BI 201335

Boehringer Ingelheim today announced a preview of the study designs for the pivotal Phase 3 clinical trials evaluating BI 201335, its investigational once-daily oral protease inhibitor, in both treatment-naive and -experienced patients with chronic genotype-1 hepatitis C virus, the most challenging genotype to treat.

2 Apr 2011

Ariz. Governor announces plan to cut Medicaid but restore some transplant funding

Gov. Jan Brewer asks HHS to approve proposal that would cut some enrollees and increase their cost sharing.

2 Apr 2011

Study findings on novel ST2 cardiac biomarker to be presented at ACC 2011

A novel cardiac biomarker, ST2, will be highlighted in three presentations at the American College of Cardiology in New Orleans this week.

1 Apr 2011

Viewpoints: The dangers of targeting the AARP; health reform in rural areas; prisoners faring better in Calif. than disabled

In hearings Friday, some of my former congressional colleagues are due to explore the operations of the AARP, the nation's oldest and largest organization representing Americans age 50 and older. Specifically, the hearing is to examine the group's tax status, evaluating it in view of its management structure and funding.

1 Apr 2011

Results of Boehringer Ingelheim's BI 201335 study presented at Annual Meeting of EASL

New data presented today at the 46th Annual Meeting of the European Association for the Study of the Liver demonstrate the antiviral activity of Boehringer Ingelheim's once-daily oral protease inhibitor, BI 201335, in both treatment-naive and -experienced patients with chronic genotype-1 hepatitis C virus, the most challenging genotype of HCV to treat.

1 Apr 2011

Donation after cardiac death may broaden the scope of organ donor selection

Findings from two new studies presented today at the International Liver CongressTM confirm that there are options for clinicians to expand the pool of liver grafts for use in patients with liver disease.

1 Apr 2011

New lifesaving technology can combat cancer

Imagine the benefits if there was technology that pinpointed exactly which chemotherapy drugs work best in fighting each individual's type of cancer. No more guessing. No more trial and error. The good news is that such lifesaving technology is on its way to becoming reality.

1 Apr 2011

OPO staff working with ICU team can help recover more organs from brain dead donors

More than twice as many lungs and nearly 50 percent more kidneys could be recovered for transplant operations if intensive care physicians were to work with organ procurement organization (OPO) coordinators to monitor and manage donor bodies after brain death has occurred, according to an analysis by UPMC and University of Pittsburgh School of Medicine physicians that is now in the online version of the American Journal of Transplantation.

1 Apr 2011

Diseased human hepatocytes successfully reprogrammed into induced pluripotent stem cells

Study shows, for the first time, the successful reprogramming of diseased human hepatocytes into induced pluripotent stem cells (iPSC).

1 Apr 2011

Scientists engineer new protein that prevents HIV virus entry into cells

In what could be a potential breakthrough in the battle against AIDS and a major development in the rational design of new drugs, scientists have engineered a new protein that prevents the virus from entering cells.

1 Apr 2011

Study confirms D-penicillamine and trientine effective against Wilson disease

Results from the first ever European-wide retrospective analysis presented today at the International Liver CongressTM have shown both D-penicillamine and trientine continue to be effective treatments, providing positive survival rates in patients with Wilson disease free from a liver transplant.

1 Apr 2011

Merck's VICTRELIS phase III study results against HCV presented at EASL annual meeting

Merck, known as MSD outside of the United States and Canada, announced results from several new data analyses from the pivotal Phase III studies evaluating the addition of its investigational oral protease inhibitor VICTRELIS to peginterferon alfa-2b and ribavirin in adult patients with chronic hepatitis C virus genotype 1 infection.

1 Apr 2011

Hands-free electronic water faucets more likely to be contaminated with hazardous bacteria

A study of newly installed, hands-free faucets at The Johns Hopkins Hospital, all equipped with the latest electronic-eye sensors to automatically detect hands and dispense preset amounts of water, shows they were more likely to be contaminated with one of the most common and hazardous bacteria in hospitals compared to old-style fixtures with separate handles for hot and cold water.

1 Apr 2011

Insight into bowel cancer

Stem cells in the intestine, which when they mutate can lead to bowel cancers, might also be grown into transplant tissues to combat the effects of those same cancers, the UK National Stem Cell Network annual science meeting will hear today.

31 Mar 2011

Master regulators of cholesterol and fat play key role in liver fibrosis development

UCLA researchers have demonstrated that a key regulator of cholesterol and fat metabolism in the liver also plays an important role in the development of liver fibrosis - the build-up of collagen scar tissue that can develop into cirrhosis. Cirrhosis, in turn, is a major cause of premature death and is incurable without a liver transplant.

31 Mar 2011

Transplant News and Research

Coronary computed tomographic angiography to evaluate acute chest pain reduces hospital admissions

Abbott and Enanta's ABT-450/r Phase 2 study results against HCV presented at EASL meeting

Optimer study highlights economic burden of acute and recurrent CDI in hospital patients

Leukemia & Lymphoma publishes CTI's CPOP phase I/II trial results against NHL

Boehringer Ingelheim's BI 201335 new data against HCV highlighted at EASL meeting

Boehringer Ingelheim advances into Phase 3 clinical trial of BI 201335

Ariz. Governor announces plan to cut Medicaid but restore some transplant funding

Study findings on novel ST2 cardiac biomarker to be presented at ACC 2011

Viewpoints: The dangers of targeting the AARP; health reform in rural areas; prisoners faring better in Calif. than disabled

Results of Boehringer Ingelheim's BI 201335 study presented at Annual Meeting of EASL

Donation after cardiac death may broaden the scope of organ donor selection

New lifesaving technology can combat cancer

OPO staff working with ICU team can help recover more organs from brain dead donors

Diseased human hepatocytes successfully reprogrammed into induced pluripotent stem cells

Scientists engineer new protein that prevents HIV virus entry into cells

Study confirms D-penicillamine and trientine effective against Wilson disease

Merck's VICTRELIS phase III study results against HCV presented at EASL annual meeting

Hands-free electronic water faucets more likely to be contaminated with hazardous bacteria

Insight into bowel cancer

Master regulators of cholesterol and fat play key role in liver fibrosis development

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News